NatureWise Biotech & Medicals Corporation

TWO:4732 Taiwan Biotechnology

Market Cap

$29.28 Million

NT$968.61 Million TWD

Market Cap Rank

#25618 Global

#1602 in Taiwan

Share Price

NT$20.10

Change (1 day)

+0.50%

52-Week Range

NT$19.35 - NT$21.40

All Time High

NT$21.40

NatureWise Biotech & Medicals Corporation - Asset Resilience Ratio

Latest as of June 2025: 55.75%

NatureWise Biotech & Medicals Corporation (4732) has an Asset Resilience Ratio of 55.75% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

NT$438.60 Million

Cash + Short-term Investments

Total Assets

NT$786.70 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how NatureWise Biotech & Medicals Corporation's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down NatureWise Biotech & Medicals Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$438.60 Million	55.75%
Total Liquid Assets	NT$438.60 Million	55.75%

Asset Resilience Insights

Very High Liquidity: NatureWise Biotech & Medicals Corporation maintains exceptional liquid asset reserves at 55.75% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.